• Skip to main content
  • Skip to primary sidebar
  • Startups
  • News
    • PC Bypoll 2021
    • Loksabha 2019
    • Assembly Elections
      • Search Name in Voters List
      • Know UR Polling Booth
    • Business
    • Letters to Editor
    • Vishwa Kannada Sammelana
    • Education
      • Did u know this
  • Infra
    • Real Estate
  • Lifestyle
    • History
      • Old Photos
      • Then & Now
    • Travel
    • Picnic spots
    • Ganesh Darshan
    • Food & Drink
    • Movies
    • ULB Polls
  • Specials
    • Stars of Belagavi
    • Trivia
    • Sports
  • City Guide
    • Weather
    • Air
    • Train
    • Bus
    • FAQ
    • IT Companies
    • KLE Centenary
    • iamBelagavi
    • Bapu – Bittoo
  • Food
  • Jobs
  • Covid19
All About Belgaum

All About Belgaum

Belagavi - Belgaum Latest News Online

belagavi
belagavi

Samarth Kulkarni from Belagavi is now CEO of Crispr Therapeutics

Oct 25, 2017 by Editor Oct 25, 2017 4 Comments

belagavi

Samarth Kulkarni, a Belgaumite recently assumed the role of CEO, Crispr Therapeutics a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases.

Dr. Samarth Kulkarni, Ph.D. has been promoted to the role of Chief Executive Officer. And he will assume the role effective December 1, 2017. Dr. Rodger Novak, M.D., co-founder and current Chief Executive Officer of CRISPR Therapeutics, is stepping down from his current role for personal reasons but will continue to serve as a member of the Company’s board of directors and as an officer of its Swiss parent company, CRISPR AG.

samarth-kulkarni Crispr Therapeutics


Dr. Kulkarni joined CRISPR Therapeutics in the company’s early stages as Chief Business Officer and has taken on positions of increasing responsibility, most recently serving as President of CRISPR Therapeutics Inc. During his tenure, both as President and Chief Business Officer, Dr. Kulkarni played a leading role in the establishment of its key collaborations with Vertex and Bayer, financing the company’s operations through its IPO, and overseeing U.S. operations.

Samarth did his schooling from Rashtriya Military School (then Belgaum Military School) and set benchmarks in his studies. He did his PUC from GSS and joined IIT Kharagpur to do his Engineering in Biotechnology and Biochemical Engineering. Later he went to the US in 2000 and completed his PhD in Biotechnology and Nanotechnology.

Dr. Samarth Kulkarni has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. He was previously a Partner at McKinsey and Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, Sam co-led the biotech practice and served a number of biotechnology companies on topics ranging from strategy to operations. Additionally, he led initiatives in areas such as personalized medicine and immunotherapy, where he co-authored several publications.

Sam received his Ph.D. in bioengineering and nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. While at the University of Washington, he conducted research in the delivery of biological drugs and in the field of molecular diagnostics, and published in numerous leading journals.

Originally from Bhagya nagar, Belagavi his proud parents are currently in USA to share his joy of promotion. The elated parents told AAB, “It is all his hard work, endurance and perseverance that has brought him to this stage. For us parents it is definitely a proud moment in our lives.

We did try to get in touch with Samarth but as he was traveling in Europe and hence we could not get his reaction.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company’s multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company’s scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com.

 

belagavi
Follow us on Google News google news belagavi

About Editor

Writes about the cozy town of Belagavi and captures all the important happenings of the city. Since 2007 have been writing on AllaboutBelagum on varied topics and impactful stories.

Reader Interactions

Comments

  1. Yash Kanabargi says

    Sep 19, 2018 at 9:41 PM

    Great inspiration sir. May good bless you and guide in your future endeavours

    Reply
  2. Amit Kulkarni says

    Oct 28, 2017 at 10:29 AM

    Heartly Congratulations Samarth.. ??

    Reply
  3. deepak dhadoti says

    Oct 27, 2017 at 1:09 AM

    amazing gt , samarth keep it up , all the best….we are proud of you ….

    Reply
  4. Nisar says

    Oct 25, 2017 at 10:52 PM

    Congratulations dear Samarth

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Search

July 2022
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
« Jun    

About Us  |  Contact us  | Advertise  |  Terms